NOVABRIDGE BIOSCIENCES (NBP) Fundamental Analysis & Valuation

NASDAQ:NBP • US44975P1030

Current stock price

2.56 USD
-0.13 (-4.83%)
At close:
2.57 USD
+0.01 (+0.39%)
After Hours:

This NBP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. NBP Profitability Analysis

1.1 Basic Checks

  • In the past year NBP has reported negative net income.
  • In the past 5 years NBP reported 4 times negative net income.
  • NBP had negative operating cash flow in 4 of the past 5 years.
NBP Yearly Net Income VS EBIT VS OCF VS FCFNBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -8.85%, NBP belongs to the top of the industry, outperforming 83.56% of the companies in the same industry.
  • With an excellent Return On Equity value of -9.48%, NBP belongs to the best of the industry, outperforming 87.43% of the companies in the same industry.
Industry RankSector Rank
ROA -8.85%
ROE -9.48%
ROIC N/A
ROA(3y)-42.77%
ROA(5y)-32.5%
ROE(3y)-60.95%
ROE(5y)-45.12%
ROIC(3y)N/A
ROIC(5y)N/A
NBP Yearly ROA, ROE, ROICNBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBP Yearly Profit, Operating, Gross MarginsNBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. NBP Health Analysis

2.1 Basic Checks

  • NBP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NBP has more shares outstanding
  • NBP has more shares outstanding than it did 5 years ago.
  • NBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NBP Yearly Shares OutstandingNBP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBP Yearly Total Debt VS Total AssetsNBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • NBP has an Altman-Z score of 4.02. This indicates that NBP is financially healthy and has little risk of bankruptcy at the moment.
  • NBP has a Altman-Z score of 4.02. This is in the better half of the industry: NBP outperforms 71.37% of its industry peers.
  • There is no outstanding debt for NBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.02
ROIC/WACCN/A
WACC8.87%
NBP Yearly LT Debt VS Equity VS FCFNBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • NBP has a Current Ratio of 14.47. This indicates that NBP is financially healthy and has no problem in meeting its short term obligations.
  • NBP's Current ratio of 14.47 is amongst the best of the industry. NBP outperforms 90.91% of its industry peers.
  • A Quick Ratio of 14.47 indicates that NBP has no problem at all paying its short term obligations.
  • NBP has a Quick ratio of 14.47. This is amongst the best in the industry. NBP outperforms 90.91% of its industry peers.
Industry RankSector Rank
Current Ratio 14.47
Quick Ratio 14.47
NBP Yearly Current Assets VS Current LiabilitesNBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NBP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.96% over the past year.
  • The Revenue for NBP has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)75.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.09%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 9.38% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.9%
EPS Next 2Y29.62%
EPS Next 3Y16.12%
EPS Next 5Y9.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NBP Yearly Revenue VS EstimatesNBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2028 2029 2030 2031 2032 2033 0 500M 1B 1.5B
NBP Yearly EPS VS EstimatesNBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.5 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. NBP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NBP. In the last year negative earnings were reported.
  • Also next year NBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBP Price Earnings VS Forward Price EarningsNBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBP Per share dataNBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NBP's earnings are expected to grow with 16.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.62%
EPS Next 3Y16.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NBP Dividend Analysis

5.1 Amount

  • NBP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NBP Fundamentals: All Metrics, Ratios and Statistics

NOVABRIDGE BIOSCIENCES

NASDAQ:NBP (3/20/2026, 8:12:24 PM)

After market: 2.57 +0.01 (+0.39%)

2.56

-0.13 (-4.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)04-01
Inst Owners31.63%
Inst Owner ChangeN/A
Ins Owners0.56%
Ins Owner ChangeN/A
Market Cap295.08M
Revenue(TTM)N/A
Net Income(TTM)-24.54M
Analysts84.44
Price Target8.57 (234.77%)
Short Float %16.49%
Short Ratio7.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.8%
PT rev (3m)0.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.25
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.85%
ROE -9.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.77%
ROA(5y)-32.5%
ROE(3y)-60.95%
ROE(5y)-45.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.47
Quick Ratio 14.47
Altman-Z 4.02
F-ScoreN/A
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)76.13%
Cap/Depr(5y)97.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.09%
EPS Next Y89.9%
EPS Next 2Y29.62%
EPS Next 3Y16.12%
EPS Next 5Y9.38%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y70.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.07%
OCF growth 3YN/A
OCF growth 5YN/A

NOVABRIDGE BIOSCIENCES / NBP Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NOVABRIDGE BIOSCIENCES?

ChartMill assigns a fundamental rating of 3 / 10 to NBP.


What is the valuation status of NOVABRIDGE BIOSCIENCES (NBP) stock?

ChartMill assigns a valuation rating of 0 / 10 to NOVABRIDGE BIOSCIENCES (NBP). This can be considered as Overvalued.


How profitable is NOVABRIDGE BIOSCIENCES (NBP) stock?

NOVABRIDGE BIOSCIENCES (NBP) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for NBP stock?

The Earnings per Share (EPS) of NOVABRIDGE BIOSCIENCES (NBP) is expected to grow by 89.9% in the next year.